Drugs / Trastuzumab-emtansin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04644432 | Mar 2020 → Sep 2022 | renal cell carcinoma | Herlev and Gentofte Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab-emtansin | “Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week” NCT04644432 ↗ |
| Route | Intravenous | “Trastuzumab-emtansin iv infusion” NCT04644432 ↗ |